Included in the formulation
АТХ:N.05.C.A Barbiturates
N.05.C.A.15 Methohexital
Pharmacodynamics:The barbituric acid derivative of short-term action (5-7 min), has a moderate analgesic effect. The CNS inhibitory effect is due to the activation of the GABAA receptor brain.
Pharmacokinetics:The maximum concentration in the blood plasma is reached after 30 seconds. The connection with plasma proteins is 73%. Freely passes through the blood-brain barrier, not deposited. Not cumulated.
The therapeutic effect develops in 30 seconds after the beginning of admission. Metabolism in the liver by oxidation and demethylation.
The half-distribution period is 5 minutes.
The half-life is 1.5 hours.
Elimination of the kidneys in the form of inactive metabolites.
Indications:Used for induction anesthesia for short-term surgical interventions as an independent agent or in combination with means for inhalation anesthesia.
XXI.Z40-Z54.Z51.4 Preparatory procedures for subsequent treatment, not elsewhere classified
Contraindications:Dysfunction of the liver, porphyria, individual intolerance to barbiturates.
Carefully:Bronchial asthma, epilepsy, neonatal period.
Pregnancy and lactation:Recommendations for FDA - Category B. It is used for life indications. During lactation, it is necessary to stop breastfeeding temporarily (for 4 days) after applying the drug.
Dosing and Administration:Application in children
It is used intramuscularly (6-10 mg / kg 5% solution) and rectally (25 mg / kg 1% solution). Intravenous administration of the drug to patients under 18 years is contraindicated.
Adults
Intravenously spray 1% solution, 0.2% solution for infusion. For an introductory narcosis lasting 5-7 minutes: 50-120 mg. To maintain anesthesia: 1% solution spray 2-4 ml (20-40 mg). With continuous drip infusion: 0.2% solution at a rate of 1 drop / s (3ml / min).
The highest daily dose: 120 mg.
The highest single dose: 10 mg.
Side effects:Central and peripheral nervous system: headache, delirium, convulsive seizures.
The cardiovascular system: tachycardia, arterial hypotension, thrombophlebitis.
Respiratory system: cough, hiccough, laryngospasm, bronchospasm, dyspnea.
Digestive system: nausea, salivation, vomiting.
Allergic reactions.
Overdose:Inhibition of the central nervous system, convulsions, pulmonary edema, cardiac arrest.
Treatment is symptomatic.
Interaction:Strengthens the action of drugs that depress the central nervous system and alcohol: with simultaneous use increases the risk of hypotension and respiratory center depression.
Strengthens the antihypertensive effect of antihypertensive drugs.
Acetylsalicylic acid and probenicid potentiate barbiturate anesthesia.
With simultaneous application with ketamine increases the risk of respiratory depression and development of hypotension, the hypnotic effect of metohexital decreases.
Simultaneous application of magnesium sulfate increases the inhibitory effect on the central nervous system.
With the simultaneous use of antipyretics, the risk of hypothermia increases.
Special instructions:Monitoring hemodynamics, oxygenation, drug concentration in the blood.